An Evidence-Based Update on Anticholinergic Use for Drug-Induced Movement Disorders.
- Published in:
- CNS Drugs, 2024, v. 38, n. 4, p. 239, doi. 10.1007/s40263-024-01078-z
- By:
- Publication type:
- Article
Works matching IS 11727047 AND DT 2024 AND VI 38 AND IP 4
Results: 6
1
2
Attention-Deficit Hyperactivity Disorder (ADHD) Medication Use Trajectories Among Women in the Perinatal Period.
- Published in:
- CNS Drugs, 2024, v. 38, n. 4, p. 303, doi. 10.1007/s40263-024-01076-1
- By:
- Publication type:
- Article
3
Current Understanding of Compulsive Sexual Behavior Disorder and Co-occurring Conditions: What Clinicians Should Know about Pharmacological Options.
- Published in:
- CNS Drugs, 2024, v. 38, n. 4, p. 255, doi. 10.1007/s40263-024-01075-2
- By:
- Publication type:
- Article
4
Magnetic Resonance Imaging Evidence Supporting the Efficacy of Cladribine Tablets in the Treatment of Relapsing-Remitting Multiple Sclerosis.
- Published in:
- CNS Drugs, 2024, v. 38, n. 4, p. 267, doi. 10.1007/s40263-024-01074-3
- By:
- Publication type:
- Article
5
SAFE-ROCK: A Phase I Trial of an Oral Application of the ROCK Inhibitor Fasudil to Assess Bioavailability, Safety, and Tolerability in Healthy Participants.
- Published in:
- CNS Drugs, 2024, v. 38, n. 4, p. 291, doi. 10.1007/s40263-024-01070-7
- By:
- Publication type:
- Article
6
The Dose-Response Relationship between Opioid Agonist Therapy and Alterations in Pain Pathways in Patients with Opioid Use Disorders: A Cross-Sectional Study.
- Published in:
- CNS Drugs, 2024, v. 38, n. 4, p. 281, doi. 10.1007/s40263-024-01069-0
- By:
- Publication type:
- Article